Hey readers! 👋
Welcome to another week of T1D news! This week's roundup is packed with updates on automated insulin delivery systems, practical CGM troubleshooting tips, and some exciting glimpses into what's coming down the pipeline. Plus, there's solid research confirming what many of us already suspected about hybrid closed-loop systems. Let's dive in!
🔬 This Week's Highlights
Sequel Med Tech Partners with Diabeloop for twiist Pump Integration marks a significant moment for automated insulin delivery in the United States. Sequel Med Tech will integrate the FDA-cleared DBLG2 algorithm into its twiist pump, making it the first commercial U.S. pump to use this European-developed system. – Joanne Milo, The Savvy Diabetic
This partnership brings together two companies with strong track records in diabetes technology. The DBLG2 algorithm has been used successfully in Europe, and its arrival stateside gives people with T1D another solid option in the growing AID landscape.
Tidepool's twiist Loop System continues to show impressive real-world results. The system predicts glucose levels every five minutes, dynamically adjusts basal insulin, and recommends boluses based on a six-hour forecast. Clinical data from the Loop Observational Study demonstrates meaningful improvements across multiple metrics. – Tidepool
"6% Improvement in TIR" and "90% Reduction in severe hypoglycemia"
The accompanying twiist App consolidates pump, CGM, and prediction data into a single dashboard with Apple Watch integration. For those who appreciate having everything in one place, this all-in-one approach simplifies the daily management load considerably.
📊 Research Worth Reading
Hybrid Closed-Loop Systems Outperform Sensor-Augmented Pumps in a comprehensive meta-analysis of 27 randomized studies involving over 1,000 participants. The research confirms that hybrid closed-loop systems deliver better glycemic control than sensor-augmented pump therapy alone. – Diabetes UK
The numbers tell a compelling story: HCLS increased time in range by 8.8% and reduced time above 10 mmol/L by 7.8%. Hypoglycemic outcomes also improved, with reductions in time below dangerous thresholds. The findings particularly support HCLS use for pediatric patients, where the benefits of automated adjustments can make a real difference in daily life.
AJMC's Type 1 Diabetes Compendium compiles recent studies highlighting advances in CGM technology, closed-loop delivery, and emerging strategies for early detection and risk modeling. – AJMC
"Structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes."
This collection emphasizes how advanced monitoring systems improve not just glucose outcomes but also sleep quality and overall quality of life, particularly for youth with T1D.
🛠️ Practical Resources
Navigating CGM Issues: A Practical Guide from Breakthrough T1D addresses those frustrating moments when your sensor readings don't match how you feel. The guide walks through troubleshooting steps and replacement procedures for all major manufacturers. – Breakthrough T1D
"Abbott offers a generous, no-charge warranty replacement program for its FreeStyle Libre CGMs, which can be mailed directly to you or picked up at a retail pharmacy."
Key takeaway: if your CGM reading differs from your symptoms by more than 20%, verify with a glucometer and contact your manufacturer's support. Each brand, including Abbott, Dexcom, Medtronic, and Senseonics, offers dedicated replacement processes, often free under warranty with expedited shipping options.
Breakthrough T1D News Roundup shares several organizational updates worth noting. Civica's affordable long-acting insulin is now available nationwide after a three-year partnership. The organization also secured a $1.5 million grant to expand care access for underserved adults and announced collaborations on new insulin therapies. – Breakthrough T1D
🔮 Looking Ahead
Future Diabetes Tech: Where Innovation Is Headed explores three areas of active development that could reshape diabetes management in coming years. – Diabetech
"Developers are working on implantable CGMs designed to stay under the skin for months at a time with little to no maintenance."
The article highlights implantable CGMs that could eliminate frequent sensor changes, bi-hormonal pumps delivering both insulin and glucagon to better mimic healthy pancreatic function, and faster-acting insulin formulations. Combined with smarter algorithms and AI integration, these advances point toward a future where diabetes management requires less mental effort and integrates more seamlessly into daily life.
📋 Quick Hits
TrialNet Risk Screening offers free screening for relatives of people with T1D, enabling early detection and potential intervention. – TrialNet
Dexcom's New CEO Addresses G7 Supply Issues with plans to prevent future shortages. – The Savvy Diabetic
Medtronic's MiniMed Go App received FDA clearance, linking smart insulin pens with Abbott's CGM for dose calculations and missed-dose alerts. – The Savvy Diabetic
💭 Final Thoughts
This week's news reflects the steady progress happening across diabetes technology. From algorithm partnerships expanding AID options to practical resources for everyday CGM challenges, the T1D community continues to benefit from innovation and collaboration. The research confirming hybrid closed-loop advantages provides solid evidence for those considering their next technology upgrade, while the glimpse into future developments offers hope for even more seamless management ahead.
Stay well, and keep those sensors calibrated!
Made with ❤️ by Data Drift Press
Have questions, comments, or feedback? Hit reply - we'd love to hear from you!